Cargando…

The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation

Background: The main dietary source of omega-3 polyunsaturated fatty acids (n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In the present manuscript, we aimed to review the current evidence regarding the clinical role of n-3 PUFA in the prevention of at...

Descripción completa

Detalles Bibliográficos
Autores principales: Christou, Georgios A., Christou, Konstantinos A., Korantzopoulos, Panagiotis, Rizos, Evangelos C., Nikas, Dimitrios N., Goudevenos, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613340/
https://www.ncbi.nlm.nih.gov/pubmed/26402674
http://dx.doi.org/10.3390/ijms160922870
_version_ 1782396263717666816
author Christou, Georgios A.
Christou, Konstantinos A.
Korantzopoulos, Panagiotis
Rizos, Evangelos C.
Nikas, Dimitrios N.
Goudevenos, John A.
author_facet Christou, Georgios A.
Christou, Konstantinos A.
Korantzopoulos, Panagiotis
Rizos, Evangelos C.
Nikas, Dimitrios N.
Goudevenos, John A.
author_sort Christou, Georgios A.
collection PubMed
description Background: The main dietary source of omega-3 polyunsaturated fatty acids (n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In the present manuscript, we aimed to review the current evidence regarding the clinical role of n-3 PUFA in the prevention of atrial fibrillation (AF) and the possible underlying mechanisms. Methods: A literature search based on PubMed listings was performed using “Omega-3 fatty acids” and “atrial fibrilation” as key search terms. Results: n-3 PUFA have been shown to attenuate structural atrial remodeling, prolong atrial effective refractory period through the prevention of reentry and suppress ectopic firing from pulmonary veins. Dietary fish intake has been found to have no effect on the incidence of AF in the majority of studies. Circulating DHA has been consistently reported to be inversely associated with AF risk, whereas EPA has no such effect. The majority of studies investigating the impact of n-3 PUFA supplementation on the incidence of AF following cardiac surgery reported no benefit, though most of them did not use n-3 PUFA pretreatment for adequate duration. Studies using adequate four-week pretreatment with n-3 PUFA before cardioversion of AF showed a reduction of the AF incidence. Conclusions: Although n-3 PUFA have antiarrhythmogenic properties, their clinical efficacy on the prevention of AF is not consistently supported. Further well-designed studies are needed to overcome the limitations of the existing studies and provide robust conclusions.
format Online
Article
Text
id pubmed-4613340
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-46133402015-10-26 The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation Christou, Georgios A. Christou, Konstantinos A. Korantzopoulos, Panagiotis Rizos, Evangelos C. Nikas, Dimitrios N. Goudevenos, John A. Int J Mol Sci Review Background: The main dietary source of omega-3 polyunsaturated fatty acids (n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In the present manuscript, we aimed to review the current evidence regarding the clinical role of n-3 PUFA in the prevention of atrial fibrillation (AF) and the possible underlying mechanisms. Methods: A literature search based on PubMed listings was performed using “Omega-3 fatty acids” and “atrial fibrilation” as key search terms. Results: n-3 PUFA have been shown to attenuate structural atrial remodeling, prolong atrial effective refractory period through the prevention of reentry and suppress ectopic firing from pulmonary veins. Dietary fish intake has been found to have no effect on the incidence of AF in the majority of studies. Circulating DHA has been consistently reported to be inversely associated with AF risk, whereas EPA has no such effect. The majority of studies investigating the impact of n-3 PUFA supplementation on the incidence of AF following cardiac surgery reported no benefit, though most of them did not use n-3 PUFA pretreatment for adequate duration. Studies using adequate four-week pretreatment with n-3 PUFA before cardioversion of AF showed a reduction of the AF incidence. Conclusions: Although n-3 PUFA have antiarrhythmogenic properties, their clinical efficacy on the prevention of AF is not consistently supported. Further well-designed studies are needed to overcome the limitations of the existing studies and provide robust conclusions. MDPI 2015-09-22 /pmc/articles/PMC4613340/ /pubmed/26402674 http://dx.doi.org/10.3390/ijms160922870 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Christou, Georgios A.
Christou, Konstantinos A.
Korantzopoulos, Panagiotis
Rizos, Evangelos C.
Nikas, Dimitrios N.
Goudevenos, John A.
The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation
title The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation
title_full The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation
title_fullStr The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation
title_full_unstemmed The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation
title_short The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation
title_sort current role of omega-3 fatty acids in the management of atrial fibrillation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613340/
https://www.ncbi.nlm.nih.gov/pubmed/26402674
http://dx.doi.org/10.3390/ijms160922870
work_keys_str_mv AT christougeorgiosa thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT christoukonstantinosa thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT korantzopoulospanagiotis thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT rizosevangelosc thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT nikasdimitriosn thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT goudevenosjohna thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT christougeorgiosa currentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT christoukonstantinosa currentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT korantzopoulospanagiotis currentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT rizosevangelosc currentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT nikasdimitriosn currentroleofomega3fattyacidsinthemanagementofatrialfibrillation
AT goudevenosjohna currentroleofomega3fattyacidsinthemanagementofatrialfibrillation